Deals & Cases

Schellenberg Wittmer acted as co-counsel for Sosei Heptares


Schellenberg Wittmer acted as co-counsel for Sosei Heptares on its acquisition of Idorsia Pharmaceuticals Ltd's pharmaceuticals business in Japan and APAC.

Sosei Group acquired all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd. The Transaction also included the assignment of the license on the lead product PIVLAZ® (clazosentan), and all territorial related intellectual property and know-how, as well as license rights to daridorexant for Japan and APAC.

The team of Schellenberg Wittmer consisted of Lorenza Ferrari Hofer (IP / Life Sciences), Tarek Houdrouge (M&A / Capital Markets), Olivier Hari (Lead M&A / Capital Markets), Alexander Zundel (M&A / Capital Markets), Jean-Frédéric Maraia (Taxation), Helen Reinhardt (IP / Life Sciences), and Gian Berner (Trainee Lawyer).


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.